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Lean Readiness – The Case of the European Pharmaceutical 
Manufacturing Industry 
 
 
 
 
 
 
 
 
Purpose – The purpose of this paper is to assess the quality practices of European 
pharmaceutical manufacturers to determine the level of readiness of this industrial sector to 
implement and/or sustain lean manufacturing (LM).  
Design/Methodology/Approach – An assessment framework developed by Al‐Najem et al. 
(2013) was adapted to evaluate how ready European pharmaceutical manufacturers are to 
implement and/or sustain lean manufacturing. Therefore, the lean readiness (LR) level of these 
organisations was assessed through six quality practices related to LM. These included:  
processes; planning and control; human resources; top management and leadership; customer 
relations; and supplier relations. One research question and three hypotheses were formulated 
and tested using a combination of descriptive statistics and non-parametric Mann-Whitney 
tests. Data was collected through a survey questionnaire distributed to 310 European 
pharmaceutical manufacturers and responded by 37 of these organisations.  
Findings – Overall, the results of this study indicate an inadequate level of LR for the 
participating firms. Simultaneously, it was concluded that factors such as company size, type 
of relationships with suppliers and ISO 9000 certification do not have an effect on the quality 
practices, and hence LR level, of European pharmaceutical manufacturing organisations. 
Practical Implications – This study provides crucial information regarding the LR level of 
European pharmaceutical manufacturers, which can now be aware of the areas in their practices 
that require further improvement towards a successful lean journey. Simultaneously, 
organisations in the pharmaceutical sector that intend to implement LM can consider the results 
of this study and evaluate their readiness level. Managers can therefore refer to this research 
and use it as a platform to take better decisions regarding what quality aspects of their 
operations need to be enhanced to successfully deploy or sustain a lean strategy. 
Originality/Value – This research is one of the very few studies that have focused on evaluating 
whether the European pharmaceutical manufacturing industry is ready to successfully 
implement or sustain LM. Therefore, this research expands the limited existent body of 
knowledge of LM in this industry. 
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1. Introduction 
Over the past two decades, both manufacturing and service industries have been severely 
affected by new technological opportunities and challenges, which have set new levels for 
global, regional, and local competition (Chowdary and George, 2011). As a consequence, the 
enormous pressure from competitors and customers, in terms of delivering greater value for 
products and services (Kumar et al., 2006), has prompted manufacturing firms to turn to 
operational excellence initiatives in order to improve the quality of their products and services 
while simultaneously reducing manufacturing costs and cycle times (Belekoukias et al., 2014; 
Arya and Jain, 2014). According to Bonavia and Marin (2006) and Garza-Reyes et al. (2012), 
one of the best systems to move towards this direction is lean manufacturing (LM). 
     Following the success of Toyota, numerous manufacturing and service organisations across 
different industries, geographical territories and sizes have applied LM practices with the aim 
of improving efficiency and productivity (Dora et al., 2013a). However, despite the reported 
tangible and intangible benefits that Toyota and other Japanese automotive manufacturers have 
experienced in their operational environments (Serrano Lasa et al., 2009), few organisations 
around the world have achieved considerable improvements from their lean efforts (Arya and 
Choudhary, 2015). For instance, Bhasin (2012) and Bhasin and Burcher (2006) concluded that 
less than 10% of the companies that pursued LM reported an overall and conclusive success. 
Many reasons are believed to lie behind this phenomenon, from which one of the most 
important is the lack of complete understanding of lean concepts and general purpose (Mostafa 
et al., 2013). Simultaneously, Dora et al. (2013a) asserted that academic studies revealed 
divergent results of lean systems adoption in different industries and sectors, while Dora et al. 
(2013a) also emphasised the need for conducting more industry-centred studies in order to 
determine whether the lean theory applies to all manufacturing and service sectors. In response 
to this statement, this study focuses on a specific sector of the pharmaceutical industry, namely: 
European pharmaceutical manufacturers.  
     Various authors have accentuated that the pharmaceutical industry has been slower than 
other industries in embracing the lean theory (O'Rourke and Greene, 2006; Wagner et al., 2009; 
Pavlović and Božanić, 2012; Selko, 2011). Reasons behind this fact involve the relatively small 
cost of goods compared to the companies’ cost structure (Selko, 2011) as well as the strict 
quality standards that characterise the pharmaceutical industry (Chowdary and George, 2011). 
Similarly as with the overall pharmaceutical industry, European pharmaceutical manufactures 
remained inert to the lean wave until the start of the 21st century, when big European 
pharmaceuticals such as Novartis, AstraZeneca and GSK initiated their lean journeys 
(Chatterjee, 2014). The European pharmaceutical industry is considered a valuable asset of the 
European economy, with the best performing ratio among all other industries in the continent, 
and with a 25 percent value of the overall global pharmaceutical industry (Nenni et al., 2014). 
However, this industry has been facing important challenges related to the increase of R&D 
costs, decline in efficiency, expiration of numerous patents (Nenni et al., 2014), which has 
resulted is a considerable drop in profits (Friedli et al., 2013). As a result, an imperative need 
for improving their operational  performance through the adoption of process excellence 
programmes such as the lean approach has emerged as an opportunity to address these 
challenges (Wagner et al., 2009; Friedli et al., 2013). 
     However, despite some evidence of the application of lean manufacturing in the 
pharmaceutical industry exists, and especially in companies such as Lundbeck, GSK and 
Novartis (Friedli et al., 2013; O'Rourke and Greene, 2006; Chowdary and George, 2011), there 
is still no consensus in the academic literature regarding the applicability of lean initiatives in 
the European pharmaceutical sector, and the capability of the latter to support lean initiatives. 
 
 
In addition, besides the reported cases of LM implementation in the pharmaceutical industry, 
there is no study in the academic literature that focuses on the exploration of the lean readiness 
(LR) level of European pharmaceutical manufacturers. In this line, Al-Najem et al. (2013), 
Garza-Reyes et al. (2015) and Anand and Kodali (2008) have highlighted the lack of 
exploratory studies regarding the LR level of other industries, besides the automotive where 
LM was born. Therefore, and considering the importance of the European pharmaceutical 
industry, this paper investigates the level of readiness of this industrial sector to provide a good 
foundation for the implementation or sustainment of the lean manufacturing. 
     Lean practices have been assessed through various frameworks proposed in the academic 
literature (Panizzolo, 1998; Mady, 2009; Furlan et al., 2011; Shah and Ward, 2003; Nordin et 
al., 2010; Gupta et al., 2013; Anand and Kodali, 2009). However, Al‐Najem et al.’s (2013) 
framework was selected as the most appropriate for this study due to it evaluates lean readiness 
(LR) based on quality practices that are considered enablers of LM  (i.e. processes; planning 
and control; human resources; top management and leadership; customer relations; and 
supplier relations). For this reason, besides providing an insight into the LR of the European 
manufacturers, it also provides understanding regarding its quality practices. 
 
2. Literature review – formulation of research question and hypotheses  
Extensive evidence suggests LM as an effective approach to aid organisation in being more 
competitive through the achievement of excellence in their operations (Belekoukias et al., 
2014; Arya and Jain, 2014). However, factors contributing to the failure in the deployment and 
sustainment of lean practices have resulted in a large number of cases being reported in the 
academic literature where lean benefits have not been realised (Arya and Choudhary, 2015; 
Bhasin and Burcher, 2006). For this reason, there is a need to assess the practices of 
organisations to determine whether these are supportive of the implementation or sustainment 
of LM, or if they need to be enhanced or adapted to support and facilitate the lean philosophy. 
In this line, organisations need to evaluate their preparedness (i.e. readiness) to support LM 
(Al‐Najem et al., 2013). This led to the formulation of the following research question: 
RQ1. Are European pharmaceutical manufacturers capable of supporting lean manufacturing 
practices? 
     Furlan et al. (2011), Shah and Ward (2003), Dahlgaard and Dahlgaard (2001), Cua et al. 
(2001) and Andersson et al. (2006) suggest that existing quality practices play a significant 
role in succeeding in the implementation and sustainment of LM. For example, Furlan et al. 
(2011) comment that quality practices can both continue supporting LM after it has been 
implemented and aid in its initial deployment. Al-Najem et al.’s (2013) assessment framework 
was developed based on this relationship between quality practices and LM. Therefore, the aim 
of this paper is not to assess the leanness (Belekoukias et al., 2014) of European pharmaceutical 
manufacturers, but to evaluate their quality practices to determine whether these organisations 
have the capabilities to implement or sustain LM. Al-Najem et al. (2013) justifies six cultural 
and technical constructs and requirements for LM, which equally have a relationship with 
quality practices. These include the whole chain of LM, moving through suppliers, internal 
processes and customers (Al-Najem et al., 2013). The constructs include: processes; planning 
and control; human resources; top management and leadership; customer relations; and 
supplier relations.  
 
2.1 Lean manufacturing in Small and Medium Size Enterprises (SMEs) 
Following Toyota’s success, countless firms around the world and across different sectors, 
regions and sizes imitated its lean system in their effort to achieve similar levels of performance 
 
 
(Dora et al., 2013b). However, it is evident that most of the scholarly articles on the LM 
literature are dedicated to its implementation in large organisations (Al-Najem et al., 2013). In 
response, recent publications have addressed the issue of LM applicability and suitability in 
the extent of SMEs (e.g. Saad et al., 2006; Dora et al., 2013b; Rose et al., 2011; Second, 2010).  
     The importance of SMEs globally, and in the European context, has been extensively 
highlighted over the past decade. More specifically, according to Saad et al. (2006), SMEs 
constitute a vital part of the manufacturing industry and simultaneously a driving force for the 
sustainability of national economies. Similarly, Bakas et al. (2011) also stressed the pivotal 
role of SMEs in the European economy, where those companies employ a huge percentage of 
the entire workforce and contribute considerably to the creation of value for customers. As far 
as the pharmaceutical sector is concerned, the European pharmaceutical industry consists of 
1301 registered SMEs, where the majority focuses on drug development (EMA, 2014). In this 
regard, the introduction of LM in SMEs constitutes an issue of major importance in the pursuit 
of achieving higher productivity in the sector. 
     When the literature is reviewed, it can be comprehended that the issue of LM applicability 
in SMEs remains questionable (Anand and Kodali, 2008; Dora et al., 2013b). On one hand, 
some authors have raised concerns over the direct adoption of LM practices in SMEs. In more 
detail, a number of factors including the lack of financial resources and strong leadership as 
well as the nature of the relationship with customers and suppliers hinder the lean journey of 
SMEs (Rose et al., 2011; Saad et al., 2006; Achanga et al., 2005). Similarly, the results of the 
researches conducted by White et al. (1999) and Golicic and Medland (2007) accentuated the 
enormous difficulties that implementing and sustaining LM imposes to SMEs. 
     However, some researches from Cua et al. (2001), Bonavia and Marin (2006) and Mallur et 
al. (2012), by examining the effect of company size when implementing lean in the area of 
Karnataka and the Spanish tile ceramic industry, concluded that large organisations and SMEs 
do not differ in their capability to adopt quality practices such as TQM and LM (Al-Najem et 
al., 2013). This observation is further supported by the studies of Karlsson and Åhlström (1997) 
and Ghobadian and Gallear (1997), which did not find any effect of the size factor on the 
capability of applying lean. Therefore, the existing literature does not provide a clear 
understanding regarding the effect of company size on the successful implementation of lean 
practices. This, in conjunction with the absence of any evidence within the context of European 
pharmaceuticals, allowed us to formulate the following hypothesis: 
H1: Small and medium-sized firms (SMEs) and large organisations differ significantly with 
regard to their quality practices in the European pharmaceutical manufacturing industry 
 
2.2 Relationship with suppliers 
The role of suppliers is critical in the implementation and sustainment of LM (Al-Najem et al., 
2013). Womack et al. (2007) were the first that indicated the significance of buyer-supplier 
relationship in the context of LM, whereas numerous others followed (Doolen and Hacker, 
2005). In this regard, Liker (2004) and Baker (2004) alleged that lean implementation must be 
diffused throughout the whole supply chain in the form of strong suppliers’ involvement 
(Bhasin and Burcher, 2006). Furthermore, Panizzolo (1998), by examining the results of lean 
implementation in 27 manufacturers, indicated that long-term relationships with suppliers in 
the form of partnership relations contribute to a more effective lean application process. This 
view can be supported by the long-established supplier contracts adopted by Toyota in order 
to achieve just-in-time (JIT) delivery (Smith and Greenwood, 1998). Other authors who have 
insisted on the imperative need of establishing long-term relationships with suppliers to enable 
 
 
the implementation of LM include Liker and Meier (2006), Chun Wu (2003) and Liker and 
Choi (2004).  
     On the other hand, the opposing view involves the risk of paying non-competitive prices 
that the buyer faces as well as the risk of reducing the efficiency of the relationship due to the 
dependency that is created (Panizzolo, 1998). In this regard, Friedli et al. (2010) provided 
evidence that the establishment of long term relationships with suppliers for the sake of some 
pharmaceutical companies which implemented JIT processes did not bring the expected results. 
Friedli et al. (2010), however, recognise that suppliers serve a critical role in the pharmaceutical 
industry and its pursuit for increase in process quality. 
     These contradictory views do not present enough evidence as to whether long-term 
relationships with supplier can serve as a basis for continuous improvement initiatives such as 
lean manufacturing. Hence, in order to contribute to the literature by examining the effect of 
supplier relationships in the case of LM in the European pharmaceutical manufacturing 
industry, the second hypothesis was formulated as follows: 
H2: There is a significant difference in the quality practices used by European pharmaceutical 
manufacturing firms with long-term supplier relationships compared to those with short-term 
relationships established 
 
2.3 ISO contribution to lean manufacturing implementation 
Various factors have been identified to contribute in the pursuit of achieving and sustaining 
competitive advantage for organisations. According to the academic literature, one of those 
factors is the ISO 9000 quality standards (Magd, 2006). In this regard, ISO 9000 is considered 
a valuable step towards continuous improvement initiatives such as TQM and LM (Al-Najem 
et al., 2013; Karthi et al., 2011; Gotzamani and Tsiotras, 2001; Sadiq Sohail and Boon Hoong, 
2003; Idris et al., 1996; Magd, 2006). Indeed Magd (2006) alleged that ISO 9000 certification 
can serve as a way to achieve continuous improvement, and as a result LM. However, there is 
no consensus in the existing literature regarding the degree to which those quality standards 
will contribute to a long-term quality assurance and a successful implementation of continuous 
improvement initiatives (Gotzamani and Tsiotras, 2001). 
     On the one hand, various studies have ascertained the involvement of ISO 9000 towards the 
implementation of LM and Six Sigma (e.g. Kumar and Antony, 2008; Al-Najem et al., 2013). 
For example, some studies have suggested that ISO 9000 serves as a basis or supplement to the 
implementation of TQM (e.g. Gotzamani and Tsiotras, 2001; Magd, 2006; Escanciano et al., 
2001). However, an opposite view is suggested by Sun (2000), who comments that ISO 9000 
offers a limited platform to support the implementation of TQM and LM. As far as the 
pharmaceutical sector is concerned, a relatively low level of ISO 9000 certification has been 
observed when compared to other industries (Freitas, 2009). This is also confirmed by the 
survey conducted by Corbett and Luca (2002), who reported that only a small percentage of 
pharmaceutical firms apply ISO 9000 in France and Sweden. However, it must be highlighted 
that no study in the literature was found to investigate the effect of ISO 9000 towards 
continuous improvement methods such as TQM or LM in the pharmaceutical industry. For all 
this, it can be concluded that there is not enough evidence in the academic literature regarding 
the effect of ISO 9000 on the implementation of LM in pharmaceutical manufacturing firms. 
As a result, the previous premises can be applied in the context of European pharmaceuticals, 
where quality assurance constitutes a critical success factor. Hence, a third hypothesis has been 
formulated as follows: 
 
 
H3: ISO 9000 certified pharmaceutical firms differ significantly with non-ISO 9000 
pharmaceutical firms in Europe regarding their quality practices 
 
3. Research methodology   
3.1 Survey questionnaire 
Since this study was concerned with the exploration and further understanding of a particular 
phenomenon (i.e. how ready the European pharmaceutical manufacturing sector is to support 
the implementation and/or sustainment of LM), the selection of an appropriate data collection 
method was vital to produce reliable evidence and obtain valid and solid conclusions (Houser, 
2008). In this case, since the subject focus was to evaluate the LR, through quality practices, 
of geographically dispersed pharmaceutical manufacturers in Europe, a survey questionnaire 
was selected as the most effective source of primary data for this research (Saunders et al., 
2012). 
     The questionnaire was created using the Qualtrics software, which respondents could easily 
access via mobile devices or web browsers. Easy storage, classification, and analysis of the 
data collected were achieved through a Qualtrics function which allowed the direct tabulation 
of the data into Excel spreadsheets. The questionnaire was adapted from that used by Al‐Najem 
et al. (2013) and Garza-Reyes et al. (2015) in their studies. It was structured in two main parts, 
consisting of a total of 56 questions. The first part comprised 9 closed questions, which 
involved both employee and company environment-related questions, the majority of which 
were designed to test the three developed hypotheses. In particular, Section 1 included 
questions related to, among other aspects, role and years of experience of the respondent, 
company’s size, application of ISO 9000, implementation of lean, etc. Section 2 consisted of a 
total of 47 questions, which were divided according to the six constructs (i.e. processes; 
planning and control; human resources; top management and leadership; customer relations; 
and supplier relations) of quality practices related to LM as defined by Al‐Najem et al. (2013). 
The questions collected both opinion and behavioural data in the form of rating type of closed 
questions. Behavioural questions were related to what the organisation was doing (e.g. how it 
was operating in relation to such quality practices), whereas opinion questions were related to 
the feelings of the respondents towards the quality practices of their companies. To achieve 
valid and reliable quantitative results, a five-item Likert scale was used for all the 47 questions 
included in the six constructs. An overview of the specific questions formulated in Section 2 
of the questionnaire is shown in Table 1. 
 
 
 
Insert Table 1 in here 
 
 
 
 
3.2 Questionnaire reliability and validity  
According to Cooper and Schindler (2013) and Crowther and Lancaster (2008), there are two 
major criteria that must be satisfied for any measurement tool to ensure credible results, 
namely: validity and reliability. On one hand, reliability refers to the consistent collection of 
the data (Saunders et al., 2012), while validity is concerned with the extent to which the used 
data collection method measures what it is supposed to measure (Lancaster, 2008). In order to 
 
 
mitigate reliability threats (i.e. subject error, participants bias, observer error, observer bias) 
(Robson, 2002; Saunders et al., 2012) and simultaneously reassure the reliability and validity 
of the questionnaire, Saunders et al. (2012) suggest the conduction of a pilot study. However, 
since the second part of the questionnaire was adapted from Al-Najem et al. (2013) and Garza-
Reyes et al. (2015), there was no need for a pilot study to be performed. Nevertheless, the 
questionnaire was sent to four academics, who provided valuable feedback for the 
improvement of the questions in terms of clarity and comprehensibility. This feedback was 
used in order to reassure the clarity of the questions as well verify the examination of the three 
hypotheses through the questions of the first part of the questionnaire. 
 
3.3 Questionnaire distribution and response rate  
The respondents were identified and randomly selected from data bases and directories such as 
Amadeus, IQS Directory, Ezilon and Global Sources. From these sources, 62 widely known 
pharmaceutical manufacturing firms were identified. Those firms operate in numerous 
countries in Europe, automatically creating a number of more than 500 possible respondents. 
However, considering the fact that some of the firms operate only in one or two European 
countries, the questionnaire was sent to an average of 10 different countries. This reduced the 
number of possible respondents to 310 firms. Initially, the questionnaire was sent via electronic 
mail, which resulted in a disappointingly low response rate. Hence, a different approach via 
LinkedIn was used in order to get contact with the appropriate employees of the selected firms. 
     Out of the 310 firms, 37 of them with operations is the UK, Switzerland, Italy, Germany, 
France, Belgium and Denmark completed the questionnaire, resulting in a response rate of 11 
percent. Although both sample size and response rate may be considered relatively small, they 
are still comparable to other similar studies in the field (e.g. Garza-Reyes et al., 2015; Devpura 
et al., 2014; Antony and Desai, 2009; Antony et al., 2007; Dolen and Hacker, 2005). While the 
sample is obviously not representative of all the European pharmaceutical manufacturers, the 
responses provided sufficient data to perform a general exploratory and statistical analysis to 
obtain some overall conclusions regarding the LR level of manufacturers operating in the 
European pharmaceutical industry.  
 
4. Results of the study 
4.1 Profile of organisations and respondents 
Figure 1 illustrates a detail profile of the European pharmaceutical manufacturing organisations 
that participated in the study. The profile data collected included: position of the individual 
respondent and his/her years of experience, number of employees and size of his/her 
organisation, whether the company was ISO 9000 certified and had implemented LM as well 
as whether it had a short or long relationship with its suppliers. In terms of the LM 
implementation, if the respondents considered that their organisations had deployed all the lean 
tools that were suitable for their companies, then this was categorised as a “complete” 
implementation, otherwise it was considered as an “incomplete” implementation.    
 
 
Insert Figure 1 in here 
 
 
4.2 Research question results 
 
 
RQ1. Are European pharmaceutical manufacturers capable of supporting lean manufacturing 
practices? 
     Based on the framework proposed by Al-Najem et al. (2013), a calculation of the mean 
scores from the five-item Likert scale was carried out, using SPSS V.23, for each of the LM-
related constructs (i.e. processes, planning and control, human resources, top management and 
leadership, customer relations and supplier relations). The results are presented in Table 2. 
 
 
 
Insert Table 2 in here 
 
 
 
 
     According to Al-Najem et al. (2013) and Nordin et al. (2010), a mean score of ≥ 4.00 is 
used as a benchmark for the segregation of capable and not capable firms when supporting the 
implementation and/or sustainment of LM initiatives. This score was adopted from the previous 
authors’ researches within the context of Kuwaiti SMEs and Malaysian automotive firms 
respectively (Al-Najem et al., 2013). Garza-Reyes et al. (2015) also adopted this approach and 
score in their study of the Turkish automotive suppliers industry. Thus, for the purpose of this 
paper, a score of ≥4 was considered as the minimum limit to indicate that the European 
pharmaceutical manufacturers surveyed were LM ready. 
     As shown by Table 2, the mean scores for the six constructs were lower than 4, indicating 
a low level of readiness to support LM initiatives. Overall, the European pharmaceutical 
manufacturing industry appears with an average mean score below 3.70 for all the constructs, 
which is considerably lower than the minimum required level (Al-Najem et al., 2013; Nordin 
et al., 2010). In particular, the highest score of 3.92 is found in the category of processes, 
indicating that European pharmaceutical manufacturers require minor development in this area 
to support LM. However, these organisations require further development in all the other 
investigated constructs (i.e. human resources, customer relations, planning and control, top 
management and leadership supplier relations) as similar scores were observed below 3.7 in all 
of these. 
 
4.3 Hypotheses results 
In this section, the data collected from both parts of the questionnaire was analysed through the 
use of descriptive and inferential statistics to test the hypotheses previously formulated. In this 
regard, descriptive tests and non-parametric Mann-Whitney (de Winter and Dou, 2010) tests 
were conducted, at a significance level of 5% (α-level = 0.05), for each hypothesis. This was 
done in order to compare the means of the independent groups and determine whether there 
was any significant difference among them. 
H1: Small and medium-sized firms (SMEs) and large organisations differ significantly with 
regard to their quality practices in the European pharmaceutical manufacturing industry 
     As it was shown in Section 4.1, 70 percent (26) of the surveyed organisations were large 
while 30 percent (11) were SMEs. The group statistics of those firms consisting of mean scores, 
standard deviations and standard error means are presented in Table 3. 
 
 
 
 
 
Insert Table 3 in here 
 
 
 
     Considering the mean scores of SMEs and large organisations, it can be seen that SMEs 
appeared to be more supportive of LM than large firms. In fact, in the processes category, 
SMEs scored a value of 4.06, higher than the minimum value of 4.0, implying a high level of 
LR. The results in the other constructs are similar as the scores of SMEs are slightly higher 
than the scores of large firms, a fact that contradicts the assumption of H1. The construct of 
planning and control is the only one that deviates from the pattern that is identified in the other 
categories, as large firms appeared to be more developed in their practices in this filed, with a 
score of 3.67 compared to the 3.44 of SMEs. Following to this analysis, a Mann-Whitney test 
was conducted to determine whether there was a significant difference in the quality practices 
of SMEs and large companies of the European pharmaceutical manufacturing industry. Null 
(H0) and alternative (H1) hypotheses were formulated regarding the absence of a significant 
difference (H0), or the existence of a significant difference between the two (H1). The results 
of the Mann-Whitney test are shown in Table 4. 
 
 
 
Insert Table 4 in here 
 
 
 
     Table 4 shows that the variances can be assumed equal in all constructs as the significance 
(2-tailed) level of the Mann-Whitney test (p-value) was > 0.05. As a result, H0 cannot be 
rejected for any of the constructs.  Furthermore, as it can be seen in Table 4, and more 
specifically the column of Significance (two-tailed), the results from the test statistics also 
reveal that H0 cannot be rejected, as the p-value is significantly higher than 0.05 in all 
categories. Consequently, the results indicate that there is not a significant difference between 
SMEs and large companies in regards to their readiness level towards LM. In other words, the 
results of the analysis suggest that a company’s size does not have any effect on the level of 
LR. However, it must be highlighted that SMEs appear to be even more supportive of LM as 
it is shown by their mean scores. 
H2: There is a significant difference in the quality practices used by European pharmaceutical 
manufacturing firms with long-term supplier relationships compared to those with short-term 
relationships established 
     Similarly as with H1, descriptive data (i.e. mean scores, standard deviations and standard 
error means) was calculated for the two groups studied. Descriptive statistics and Mann-
Whitney tests were also conducted to investigate whether there was a significant difference, in 
terms of quality practices, between European pharmaceutical manufacturing firms that had 
long-term relations with their suppliers and those that had short-term relations. Thus, this 
hypothesis aimed at exploring the effect that supplier relations may have on the adoption or 
development of quality practices, and hence the LR level of organisations. The results are 
presented in Tables 5 and 6.     
 
 
Insert Table 5 in here 
 
 
 
 
Insert Table 6 in here 
 
 
 
     As it can be observed from the column of mean scores in Table 5, the results vary regarding 
the capability of the two examined groups to support lean initiatives. To be more specific, in 
the constructs of processes and supplier relations, 31 out of the 37 participating organisations 
with long-term established relationships with their suppliers, were found to be more developed 
and capable of implementing or sustaining LM, but with mean scores lower than the critical 
value of 4.0. On the other hand, 6 companies with short-term supplier relations were found to 
have better practices in the fields of planning and control, customer relations, human resources 
and top management and leadership. Indeed, the highest difference is observed in the factor of 
top management and leadership, where the European pharmaceutical manufacturers with short-
term relationships scored a value of 3.80, compared to 3.51 of the opposite group. In total, by 
only considering the mean scores of Table 5, all of which range between 3.46 and 3.96, these 
do not differ significantly for the compared groups of firms, indicating similar practices 
towards LM. 
     For the Mann-Whitney test, a null hypothesis (H0) regarding a lack of difference in the LR 
level between firms with long and short-term relations with their suppliers was established. 
Accordingly, an alternative hypothesis (H1) that inferred a difference between these two groups 
was also formulated. The Mann-Whitney test, see Table 6, showed that the p-values for all 
constructs are higher than the significance level of 0.05, and as a result all variances can be 
assumed equal for all the categories. In other words, the null hypothesis (H0) cannot be rejected 
for any of the examined constructs. In terms of the test statistics, the results are similar to those 
obtained for H1, revealing considerably greater p-values (Sig. two-tailed) than the significance 
level of 0.05. Consequently, it can be confirmed that there is not a significant difference 
between the two groups in their practices. For this reason, the null hypothesis (H0) was 
accepted while the formulated main hypothesis from literature review H2 was rejected. This 
indicates that the nature of supplier relations does not have an effect on the LR level of 
European pharmaceutical manufacturers. 
H3: ISO 9000 certified pharmaceutical firms differ significantly with non-ISO 9000 
pharmaceutical firms in Europe regarding their quality practices 
     From the respondent companies, 20 were ISO 9000 certified while the rest (17) were not. 
However, since 3 of the 20 ISO certified firms had adopted lean first, and then obtained the 
ISO 9000 certification, these three companies were excluded from the analysis. Group 
statistics, for the two groups of 17 companies, including mean scores, standard deviations and 
standard error means were calculated. The results are presented in Table 7. As can be seen form 
this table, apart from the processes construct, where ISO certified firms prevailed over the non-
ISO certified firms with a mean score of almost 3.93 and 3.92 respectively, in all other 
constructs non-ISO organisations were found to be more supportive towards LM. However, as 
the mean scores were almost identical within the two groups, no evidence can be provided to 
conclude that ISO 9000 certified organisations differ from non-ISO 9000 companies in their 
quality practices, and hence LR level. To statistically test this, a Mann-Whitney test was carried 
out. For this, a null hypothesis (H0) that inferred a non-significant difference in quality 
practices between ISO 9000 and non-ISO 9000 organisations as well as an alternative 
hypothesis (H1) which predicted a significant difference between these two groups were posed. 
The results of the Mann-Whitney test are presented in Table 8.   
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     As illustrated in Table 8, the Mann-Whitney test revealed that all p-values were higher than 
the significance level (2-tailed) of 0.05 in all the evaluated constructs, indicating that equal 
variances can be assumed for the two groups in all categories. As a result, the null hypothesis 
(H0) cannot be rejected for any of the constructs. Additionally, the results from the test 
statistics, which provide the significance levels of the two-tailed test for every considered 
factor, suggest that there is not a significant difference between ISO 9000 and non-ISO 
companies with the context of their quality practices. This is confirmed from the fact that all 
p-values were much higher than the significance level of 0.05, and as a result the null 
hypothesis (H0) was accepted. Therefore, similarly to H1 and H2, hypothesis H3 was rejected 
for all the constructs of the European pharmaceutical manufacturers, a fact that indicates the 
neutral effect of the ISO factor on the LR level. 
 
5. Discussion of results 
RQ1. Are European pharmaceutical manufacturers capable of supporting lean manufacturing 
practices? 
     The results obtained from the analysis suggest that the participating European 
pharmaceutical manufacturers are still far from being supportive towards the adoption and/or 
sustainment of LM in their operations. This finding is in line with the observation of D’souza 
et al. (2007), who asserted that the majority of pharmaceutical companies have left behind the 
improvement of their manufacturing practices, as change in this area is mainly driven by 
compliance issues. According to Friedli et al. (2013), the pharmaceutical industry has focused 
on manufacturing products that just comply with current good manufacturing practices 
(cGMPs), without aiming at achieving excellence in their manufacturing operations. This could 
explain the results obtained from this research. In further support of the research outcome, the 
vice-president of operations of AstraZeneca claimed that manufacturing is not considered a 
core activity in the pharmaceutical industry (Friedli et al., 2013) and as a result, the 
improvement of manufacturing practices has been neglected. 
     Although the results of this study support some elements of the literature, they may 
constitute an unexpected outcome. The majority of the participating firms have already 
implemented LM, partially or fully, and therefore they may have been expected to already have 
adequately developed their quality practices. The literature is full of references of LM in the 
pharmaceutical industry (Nenni et al., 2014), and also of successful lean stories for large 
pharmaceutical manufacturers such as Lunbeck (Houborg, 2010), GSK (Carleysmith et al., 
2009), Novo Nordisk, Novartis and Abbott pharmaceuticals (Friedli et al., 2013), all of which 
reported remarkable improvements in their manufacturing operations. Thus, keeping in view 
the significant amount of time that an operational excellence approach such as LM requires for 
its full deployment (Friedli et al., 2013), the results obtained from this research may be 
explained based on the assumption that the participant organisations were in the early stages 
of the LM implementation.  
 
 
     In terms of the specific constructs, processes constituted the most develop among the 
participant firms as it achieved the highest mean score of 3.92. Within this construct, the 
strongest practice was that of personnel that control and operates the working zones, see Table 
1, which was found to have a mean score of 4.38. This indicates the attention that has been 
given to the recruitment of qualified employees within the European pharmaceutical 
manufacturing industry, and can be attributed to the low level of automation in this industry, 
which mainly relies on manual processes (Friedli et al., 2013). In this regard, Friedli et al. 
(2013) also highlighted the huge investments from pharmaceutical firms to bringing in high 
skilled resources over the past decade. On the other hand, the practice regarding the revision 
of cycle time for each product obtained one of the lowest scores (3.55) in the category of 
processes. This corroborates the findings of Shah (2004), who highlighted the lengthy cycle 
times in the pharmaceutical supply chain, and hence suggests that a minor development has 
been achieved in this area over the past decade.  
     The second highest scored construct was that of human resources (3.69), the importance of 
which in quality practices has been highlighted by various authors such as Achanga et al. 
(2005) and Furlan et al. (2011). Within this construct, the statement related to multitasking 
workers, see Table 1, obtained the highest score (3.97). This is in accordance with one of the 
principles of LM, which requires multiple tasks to be performed by workers in a specific work 
cell (McDonald et al., 2009). This is in accordance with the findings in the previous explained 
construct of process regarding the emphasis that has been given to the human factor within the 
European pharmaceutical manufacturing industry. On the hand, the practice of employees 
feedback, see Table 1, obtained the lowest score. This result indicates the need for more 
involvement of the employees of the European pharmaceutical manufacturing industry in the 
improvement of the manufacturing processes of their organisations, which constitutes a major 
requirement in LM (Hasle et al., 2012). 
     From all the six constructs, supplier relations constituted the least developed (3.52) for the 
case of European pharmaceutical manufacturers. Within this construct, the least developed 
practice corresponded to that of the inspection of raw materials; see Table 1, which suggests a 
lack of trust between the participating firms and their suppliers. This result puts into question 
the long-term relations that the majority of the respondents had established with their suppliers, 
as by considering that, a more trustful relationship, and in turn less inspection, of the purchased 
raw materials would have been expected. Therefore, despite the long-term contracts with their 
suppliers, the participating firms have not yet improved their actual relations with the latter, 
resulting on poor exploitation of the benefits that this kind of relationships provides (Womack 
et al., 1990). Similarly, the second lowest score (3.29) was attributed to the practices of on-
time delivery from the suppliers, which apparently fail to satisfy the need of their buyers in this 
respect. This is in accordance with the findings of Friedli et al. (2013), who reported the failure 
of long-term supplier relations to achieve JIT delivery. 
 
 
H1: Small and medium-sized firms (SMEs) and large organisations differ significantly with 
regard to their quality practices in the European pharmaceutical manufacturing industry 
     This hypothesis examined whether the company size had a direct effect on the quality 
practices used by the participating firms. In general, the results of the study suggested that both 
large and SMEs European pharmaceutical manufacturing companies are similar in their quality 
practices. This result contradicts the findings of various authors including Bakas et al. (2011), 
White et al. (1999), Second (2010), Golicic and Medland (2007), and Shah and Ward (2003), 
 
 
who accentuated that the size factor affects the application of LM practices in terms of major 
obstacles for SMEs compared to large organisations. On the contrary, the results are consistent 
with the findings of another group of authors, e.g., Garza-Reyes et al. (2015), Mallur et al. 
(2012), Bonavia and Marin (2006) and Al-Najem et al. (2013), who suggested that there is no 
difference between SMEs and large organisations in supporting LM.  
     Besides the negligible difference between the participating SMEs and large pharmaceutical 
manufacturers in their current practices, it could also be observed that the former were found 
to be more supportive towards LM practices as their mean scores indicate. However, as the 
survey did not involve questions or interviews regarding the factors affecting those practices 
(Al-Najem et al., 2013), it is difficult to identify the specific reasons behind the results within 
the context of the first hypothesis. Nevertheless, these results can be attributed to the upswing 
of SMEs, which appear to now be playing a leading role in the world’s economies (Schlogl, 
2004). Additionally, and as suggested by Bakas et al. (2011), SMEs  have a narrower 
hierarchical structure, which coupled with the absence of bureaucratic procedures might 
facilitate the implementation and/or sustainment of LM.  
H2: There is a significant difference in the quality practices used by European pharmaceutical 
manufacturing firms with long-term supplier relationships compared to those with short-term 
relationships established 
     This hypothesis investigated whether the established relationships between the participating 
organisations and their suppliers had an effect on their quality practices and level of LR. The 
results of the study indicated that there was not statistical evidence to suggest the existence of 
a significant difference in the quality practices used by European pharmaceutical 
manufacturing firms with long-term supplier relationships compared to those with short-term 
relationships. This result is consistent with the findings of Friedli et al. (2010), who reported 
the disappointing results of a group of pharmaceutical firms that had established long-term 
contracts with their suppliers in their effort to implement JIT processes. Long-term 
relationships, however, seem to be more supportive for the construct of processes. This result 
is in accordance with the majority of researches in the field of LM, which suggest the diffusion 
of this approach to the whole supply chain, which starts with the establishment of long-term 
relations with the main suppliers (Panizzolo, 1998). 
     In addition to the above, the results of this research do not only fail to provide evidence of 
different quality practices of the participating firms based on their relations with suppliers but 
also question the findings of numerous researches with respect to LM and supplier relations. 
For example, the subject of Supply Chain Management and supplier relations, in terms of their 
selection processes, has been discussed by numerous authors in the academic literature, 
including Kirytopoulos et al. (2008) for the case of Greek pharmaceuticals and Helper (1991). 
In this case, Kirytopoulos et al. (2008) highlighted the crucial importance of a qualified and 
reliable supplier for success in the pharmaceutical industry, whereas Helper (1991) stressed the 
need for long-term relations with suppliers in order to effectively implement LM. In contrast, 
the results obtained from this study contradict these findings, indicating that there must be 
further research and discussion on this subject in order to generate more reliable conclusions.  
H3: ISO 9000 certified pharmaceutical firms differ significantly with non-ISO 9000 
pharmaceutical firms in Europe regarding their quality practices 
     This hypothesis aimed at investigating the effect of ISO 9000 on the quality practices and 
LR level of European pharmaceutical manufacturers. In general, the results of this study 
indicated that ISO 9000 certification has no effect on the quality practices, and hence LR level, 
of European pharmaceutical manufacturers. This is in line with findings of Al-Najem et al. 
 
 
(2013), Sun (2000), Williams (1997) and Taylor (1995), who claimed that ISO 9000 does not 
serve as a platform for quality excellence programmes such as LM and TQM. Indeed, as Al-
Najem et al. (2013) discovered for the case of Kuwaiti SMEs, ISO 9000 only contributes to the 
training of the workforce and managers. 
     On the other hand, the findings of this study contradict those of other scholars including 
Karthi et al. (2011), Gotzamani and Tsiotras (2001), Sadiq Sohail and Boon Hoong (2003), 
Idris et al. (1996) and Magd (2006), who asserted that ISO 9000 provides a significant 
improvement of the quality practices within the firms and simultaneously constitute a decisive 
step towards LM practices or TQM. For instance, Gotzamani and Tsiotras (2001) suggested 
that there is a considerable difference between Greek ISO and NON-ISO firms in their 
performance for the constructs of human resources, supplier and customer relations, leadership 
and quality related processes. Similarly Magd (2006) accentuated the contribution of ISO 9000 
in the quality practices of Saudi firms. However, those conclusions cannot be confirmed for 
the case of European pharmaceutical manufactures. To conclude, the findings of this study, in 
conjunction with those of Al-Najem et al. (2013), Sun (2000), Williams (1997) and Taylor 
(1995), imply the negligible effect of ISO 9000 certification to operational excellence 
programmes, and by extension to the LR level. 
 
6. Conclusions, practical and theoretical implications, limitations and further research 
This paper investigates the LR level of the European pharmaceutical manufacturing industry 
through the study of some quality management practices related to LM. Overall, the results of 
the study suggest that European pharmaceutical manufacturing firms still require further 
development in all the investigated constructs (i.e. processes; planning and control; human 
resources; top management and leadership; customer relations; and supplier relations) of the 
practices if they are to effectively support or sustain LM. 
     In terms of the practical contributions of this research, its findings have relevant practical 
implications for the European pharmaceutical manufacturing industry. For instance 
pharmaceutical manufactures in Europe that intend to apply, or have already implemented, LM 
can refer to the findings of this research in order to identify whether they are or can be 
supportive of operational excellence initiatives such LM. In this case, the literature review in 
conjunction with the findings of the survey present those factors that must be enabled before 
implementing LM. Simultaneously, the participating firms that have already implemented LM 
have the opportunity to identify the areas where further development is required in order to 
reach the desired level of LR. Finally, as the current state of LM in the European 
pharmaceutical sector is examined, the results of this study can serve as a tool for the 
benchmarking of this industry. The theoretical contribution of this paper has been highlighted 
in Section 1, where it has been established that the academic literature lacks of a consensus 
regarding the applicability of LM in the European pharmaceutical manufacturing sector as well 
as the capability of the latter to support lean initiatives. Therefore, this research contributes by 
expanding the limited body of knowledge regarding LM in the European pharmaceutical 
manufacturing sector. In addition, the results of this research can be compared with those of 
similar researches in other industries and/or countries to determine, for example, what factors 
endowments, and to what extent, play a role and have an effect on the level of LR of different 
industries and countries.     
     Limited sample size (i.e. 37) and a five-item Likert scale, which does not give the 
respondents the opportunity to express their opinion in more detail, are considered the main 
limitations of this study. These are important to be highlighted for future studies to consider 
them when replicating, expanding or conducting similar researches. Hence, future research can 
 
 
be conducted with a larger sample size and the inclusion of interviews to capture relevant 
qualitative information regarding, for example, the reasons behind the responses that were 
collected. Further insight into the LR level of European pharmaceutical organisations will be 
achieved by incorporating these two strategies when expanding this research.    
     Future research can also be specifically focused on either large or SMEs within the 
European pharmaceutical manufacturing industry. This would provide more specific 
knowledge regarding the characteristics that enable, or hinder, the implementation or 
sustainment of LM in this industry according to the company’s size. Finally, three different 
factors, namely: company size, supplier relations and ISO 9000 certification, were examined 
regarding their effect on LR. Future research can also evaluate the influence of other factors 
such as location and financial conditions on LR to further develop the understanding of this 
phenomenon in the European pharmaceutical manufacturing sector. 
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Table 1. Items for Section 2 of the questionnaire (adapted from Al-Najem et al., 2013 and 
Garza-Reyes et al., 2015) 
 Practices Practices 
Pr
oc
es
se
s 
5S 1. The workshop is divided into different workplaces and each zone has a specific task. 
Cellular 
manufacturing 
2. The processes used within similar operations are placed close to each other in order to eliminate 
unnecessary steps. 
Skilled people 3. Each working zone is controlled and operated by qualified and well-trained workers. 
5S 4. Each item/piece of equipment is labelled to ensure it is located in the right zone/location in the workplace. 
Pull 5. Production at each station is pulled by demand from the next station. 
5S and 
standardisation 
6. A certain person is assigned as part of his daily activities to ensure that the workplace is clean and 
all tools/pieces of equipment are put back in their appropriate places. 
TPM 7. Equipment maintenance records are posted on the shop floor to be actively shared with employees. 
Cellular 
manufacturing 
8. The process flow of material and components is smooth and continuous, as the equipment is 
grouped. 
Pull 9. Products are not produced unless orders for them are received from customers. 
 
 
TPM 10. Machine operators and staff are engaged in the scheduled maintenance of equipment so that machines are maintained on a regular basis by skilled people.  
Documentation 11. There is a well-documented configuration setting for each machine/piece of equipment to avoid uncertainty about how to reconfigure the equipment during changeover. 
Standardisation 12. The total cycle time is revised for each product on a regular basis in order to reach the optimum level. 
Pl
an
ni
ng
 a
nd
 
C
on
tr
ol
 
Problem solving 
13. In order to improve production, a focus group of workers is conducted (on a regular basis) to help 
the company identify wastes and solve problems by generating new ideas and solutions, which are 
then submitted to the managers. 
Benchmarking 14. There is an awareness of the wider industry performance, and a clear strategy is followed to benchmark performance with the top-class firm (at a domestic and national level). 
Standardisation 15. There are standard routes for loading raw materials and removing end products, including a standard picking time. 
Problem solving 16. Problem-solving techniques such as Fishbone diagrams are used to identify the causes of quality problems. 
VM/KPI 17. Up-to-date charts showing defect rates, key performance indicators, progress and next job activity are displayed on the shop floor. 
C
us
to
m
er
 R
el
at
io
ns
 
Customer 
awareness 18. There is awareness of what product features customers value and are willing to pay for. 
Customer feedback 19. Feedback is sought regularly, and surveys/meetings are often held with customers to improve product design and quality, and service. 
Customer 
involvement 20. Customers participate in the initial design process.  
Customer 
relationship 
21. Valued customers are brought into visit the plant in order to provide some ideas about quality 
control that the company can follow. 
Customer 
involvement 22. Customers help the company by providing information about their future demands. 
Customer 
involvement 
23. There is a system in place for collecting customer complaints so that problems can be avoided in 
the future. 
Su
pp
lie
r 
R
el
at
io
ns
 
Quality suppliers 24. A clear strategy is in place by which to evaluate supplier performance in terms of quality, delivery and prices. 
Close suppliers 25. Local suppliers are used to avoid shipment delays. 
Supplier 
involvement 26. Suppliers are aware of product designs and participate heavily during design and development. 
Quality suppliers 27. Raw materials and purchased parts are not subject to incoming inspection as they come from qualified suppliers. 
No. of suppliers 28. Active steps are taken to reduce the number of suppliers in each category. 
Quality suppliers 29. Raw materials are received on time from the date of order. 
Supplier relation 30. Suppliers are cooperative and committed to maintaining a long-term relationship. 
Feedback to 
suppliers 31. Suppliers are provided with feedback regarding quality and delivery performance. 
H
um
an
 R
es
ou
rc
es
 
Involvement 32. Workspace layout is reconfigured regularly based on feedback from employees. 
Multi-tasking 33. Workers are able to perform different tasks. 
Participation 34. Shop-floor employees drive suggestion programme. 
Motivation 
35. Numerous awards, incentive programmes and annual bonuses are available for employees who help 
to improve processes and eliminate unnecessary steps. The evaluation is based on group 
performance. 
Skilled People 36. Workers are qualified enough to contribute to solving problems, and are able to work as a team. 
Communication 37. Departmental and employee relations are good, and conflict barely occurs. 
Involvement 38. Each employee has a clear understanding of his job description. 
Training 39. Employees have undergone quality training in terms of developing their problem-solving capabilities and identifying non-value-adding activities. 
Empowerment 40. Workers are empowered to stop the production line if abnormalities occur. 
Participation 41. Suggestions and ideas from shop-floor employees are actively used and implemented. 
Teamwork 42. Employees act according to the interests of the group, rather than their individual interests. 
T
op
 
M
an
ag
em
en
tVisible 
management 43. Top management encourages and coaches workers by visiting the workplace on a regular basis. 
Knowing people’s 
capabilities 44. We locate our worker where they can use their skills, qualifications and experience. 
 
 
Job security 45. People have job security and workers are regularly promoted to managerial positions. 
Commitment to 
improvement 46. Company invests in training programmes and encourages cross-job training. 
Commitment to 
improvement 
47. Company uses external experts/consultants on a regular basis to evaluate the overall company 
performance and to improve production and quality level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Mean scores of European pharmaceutical manufacturers 
 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
Processes 37 2.75 5.00 3.92 .614 
Planning and Control 37 2.20 5.00 3.60 .823 
Customer Relations 37 1.67 5.00 3.64 .727 
Supplier Relations 37 2.75 4.90 3.55 .480 
Human Resources 37 2.00 5.00 3.69 .707 
Top Management and 
Leadership 37 2.20 5.00 3.57 .709 
All Items 37 2.20 5.00 3.7 0.546 
Valid N (listwise) 37  
 
 
 
 
 
Table 3. Group statistics for SMEs and large firms 
Group Statistics  
 Company Size N Mean Std. Deviation 
Std. Error 
Mean 
Processes SMEs Large Companies 
11 
26 
4.06 
3.87 
.668 
.594 
.201 
.116 
Planning and 
Control 
SMEs 
Large Companies
11 
26 
3.44 
3.67 
.999 
.748 
.301 
.147 
Customer 
relations 
SMEs 
Large Companies
11 
26 
3.7 
3.61 
.623 
.777 
.188 
.152 
Supplier 
relations 
SMEs 
Large Companies
11 
26 
3.69 
3.49 
.507 
.464 
.153 
.091 
Human 
Resources 
SMEs 
Large Companies
11 
26 
3.71 
3.68 
.845 
.658 
.255 
.129 
Top 
Management 
and Leadership 
SMEs 
Large Companies 
11 
26 
3.67 
3.52 
.878 
.640 
.265 
.126 
All Items SMEs Large Companies 
11 
26 
3.76 
3.67 
.644 
.511 
.194 
.100 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Mann-Whitney test for H1 
 
Ranks 
 Company Size N Mean Rank Sum of Ranks 
Processes 
SMEs 11 20.95 230.50 
Large Companies 26 18.17 472.50 
Total 37   
Planning and Control 
SMEs 11 17.23 189.50 
Large Companies 26 19.75 513.50 
Total 37   
Customer Relations 
SMEs 11 19.95 219.50 
Large Companies 26 18.60 483.50 
Total 37   
Supplier Relations 
SMEs 11 21.14 232.50 
Large Companies 26 18.10 470.50 
Total 37   
Human Resources 
SMEs 11 19.05 209.50 
Large Companies 26 18.98 493.50 
Total 37   
Top Management    
and Leadership 
SMEs 11 20.77 228.50 
Large Companies 26 18.25 474.50 
Total 37   
All Items 
SMEs 11 20.05 220.50 
Large Companies 26 18.56 482.50 
Total 37   
 
Test Statistics 
 Mann-Whitney U Wilcoxon W Z Asymp. Sig. (2-tailed) Exact Sig. [2*(1-tailed Sig.)] 
Processes 121.500 472.500 -.716 .474 .481 
Planning and 
Control 123.500 189.500 -.651 .515 .523 
Customer Relations 132.500 483.500 -.351 .726 .731 
Supplier Relations 119.500 470.500 -.788 .431 .441 
Human Resources 142.500 493.500 -.017 .987 .987 
Top Management 
and Leadership 123.500 474.500 -.652 .514 .523 
All Items 131.500 482.500 -.382 .702 .707 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Group statistics for companies with short and long-term relationships with their 
suppliers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Statistics  
 What kind of relationship 
the company has 
established with its major 
suppliers? 
N Mean Std. Deviation 
Std. Error 
Mean 
Processes Short-term relationships Long-term relationships 
6 
31 
3.76 
3.96 
.576 
.626 
.218 
.114 
Planning and 
Control 
Short-term relationships 
Long-term relationships
6 
31 
3.69 
3.58 
.527 
.884 
.199 
.161 
Customer 
Relations 
Short-term relationships 
Long-term relationships
6 
31 
3.74 
3.61 
.833 
.714 
.315 
.130 
Supplier 
Relations 
Short-term relationships 
Long-term relationships
6 
31 
3.46 
3.57 
.483 
.485 
.182 
.089 
Human 
Resources 
Short-term relationships 
Long-term relationships
6 
31 
3.79 
3.67 
.625 
.732 
.236 
.134 
Top 
Management 
and Leadership 
Short-term relationships 
Long-term relationships 
6 
31 
3.80 
3.51 
.566 
.737 
.214 
.134 
All Items Short-term relationships Long-term relationships 
6 
31 
3.71 
3.69 
.488 
.566 
.185 
.103 
 
 
Table 6. Mann-Whitney test for H2 
Ranks 
 
 
Kind of 
relationship the 
company has 
established with its 
major suppliers N Mean Rank Sum of Ranks 
Processes 
Short term relations 6 15.93 111.50 
Long term relations 31 19.72 591.50 
Total 37   
Planning and 
Control 
Short term relations 6 19.93 139.50 
Long term relations 31 18.78 563.50 
Total 37   
Customer 
Relations 
Short term relations 6 20.07 140.50 
Long term relations 31 18.75 562.50 
Total 37   
Supplier Relations 
Short term relations 6 17.71 124.00 
Long term relations 31 19.30 579.00 
Total 37   
Human Resources 
Short term relations 6 20.50 143.50 
Long term relations 31 18.65 559.50 
Total 37   
Top Management 
and Leadership 
Short term relations 6 22.64 158.50 
Long term relations 31 18.15 544.50 
Total 37   
All Items 
Short term relations 6 18.64 130.50 
Long term relations 31 19.08 572.50 
Total 37    
 
Test Statistics 
 Mann-Whitney U Wilcoxon W Z Asymp. Sig. (2-tailed) Exact Sig. [2*(1-tailed Sig.)] 
Processes 83.500 111.500 -.835 .404 .413 
Planning and 
Control 98.500 563.500 -.253 .800 .805 
Customer Relations 97.500 562.500 -.292 .770 .776 
Supplier Relations 96.000 124.000 -.352 .725 .747 
Human Resources 94.500 559.500 -.408 .683 .690 
Top Management 
and Leadership 79.500 544.500 -.995 .320 .330 
All Items 102.500 130.500 -.097 .923 .925 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Group statistics for ISO and non-ISO certified organisations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
Group Statistics 
 Have you ever 
applied ISO 
9000 in the 
company? 
N Mean Std. Deviation Std. Error Mean 
Processes ISO Non-ISO 
17 
17 
3.93 
3.92 
.605 
.637 
.147 
.142 
Planning and 
Control 
ISO 
Non-ISO 
17 
17 
3.55 
3.64 
.899 
.775 
.218 
.173 
Customer Relations ISO Non-ISO 
17 
17 
3.60 
3.67 
.842 
.635 
.204 
.142 
Supplier Relations ISO Non-ISO 
17 
17 
3.51 
3.58 
.409 
.541 
.099 
.121 
Human Resources ISO Non-ISO 
17 
17 
3.52 
3.83 
.710 
.690 
.170 
.154 
Top Management 
and Leadership 
ISO 
Non-ISO 
17 
17 
3.48 
3.64 
.700 
.727 
.132 
.125 
All Items ISO Non-ISO 
17 
17 
3.63 
3.75 
.543 
.557 
.132 
.125 
 
 
Table 8. Mann-Whitney test for H3 
Ranks 
 
Firm’s 
Certification N Mean Rank Sum of Ranks 
Processes 
Non-ISO 9000 17 19.00 380.00 
ISO 9000 17 19.00 323.00 
Total 34   
Planning and 
Control 
Non-ISO 9000 17 19.45 389.00 
ISO 9000 17 18.47 314.00 
Total 34   
Customer 
Relations 
Non-ISO 9000 17 18.68 373.50 
ISO 9000 17 19.38 329.50 
Total 34   
Supplier 
Relations 
Non-ISO 9000 17 19.63 392.50 
ISO 9000 17 18.26 310.50 
Total 34   
Human 
Resources 
Non-ISO 9000 17 20.45 409.00 
ISO 9000 17 17.29 294.00 
Total 34   
Top 
Management 
and Leadership 
Non-ISO 9000 17 20.18 403.50 
ISO 9000 17 17.62 299.50 
Total 34   
All Items 
Non-ISO 9000 17 19.90 398.00 
ISO 9000 17 17.94 305.00 
Total 34   
 
Test Statistics 
 Mann-Whitney U Wilcoxon W Z Asymp. Sig. (2-tailed) Exact Sig. [2*(1-tailed Sig.)] 
Processes 170.000 323.000 .000 1.000 1.000 
Planning and 
Control 161.000 314.000 -.275 .783 .798 
Customer 
Relations 163.500 373.500 -.199 .842 .845 
Supplier 
Relations 157.500 310.500 -.384 .701 .707 
Human 
Resources 141.000 294.000 -.885 .376 .390 
Top 
Management 
and Leadership 
146.500 299.500 -.721 .471 .478 
All Items 152.000 305.000 -.549 .583 .598 
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Figure 1. Profile overview of organisations and respondents – (a) Role of respondents and (b) 
years of experience, (c) Number of company’s employees and (d) size,  (e) ISO 9000 
certification, (f) LM implementation, (g) relationship with suppliers 
 
